Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
University of Utah · Huntsman Cancer Institute · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
644
total citations
- FWCI
- 63.24
- Percentile
- 100%
- References
- 47
Citations per year
Authors
23- CGConan G. KinseyCorresponding
University of Utah, Huntsman Cancer Institute
- SASoledad A. Camolotto
University of Utah, Huntsman Cancer Institute
- ABAmélie Boespflug
Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, Inserm, University of Utah, Huntsman Cancer Institute, Hôpital Lyon Sud, Centre de Recherche en Cancérologie de Lyon
- KPKatrin P. Guillen
University of Utah, Huntsman Cancer Institute
- MFMona Foth
University of Utah, Huntsman Cancer Institute
Topics & keywords
Topics
Keywords
- Trametinib
- Autophagy
- KRAS
- Cancer research
- MAPK/ERK pathway
- Neuroblastoma RAS viral oncogene homolog
- MEK inhibitor
- Pancreatic cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.